A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (ISLAND2)
A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
California
-
La Jolla, California, Forenede Stater, 92037
- Scripps Clinic
-
-
Florida
-
Orlando, Florida, Forenede Stater, 32803
- Central Florida Pulmonary Group, PA
-
-
Illinois
-
Elk Grove, Illinois, Forenede Stater, 60007
- Suburban Lung Associates
-
-
Indiana
-
Muncie, Indiana, Forenede Stater, 47303
- Medical Consultants, PC ; Pulmonary
-
-
Kentucky
-
Louisville, Kentucky, Forenede Stater, 40202-1798
- University of Louisville
-
-
Louisiana
-
New Orleans, Louisiana, Forenede Stater, 70112
- Tulane University Medical School
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02135
- Steward St. Elizabeth's Medical Center ; Pulmonary, Critical Care and Sleep Medicine
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68131
- Creighton University Medical Center
-
-
Nevada
-
Reno, Nevada, Forenede Stater, 89503
- Allied Clinical Research
-
-
New Jersey
-
Summit, New Jersey, Forenede Stater, 07901
- Atlantic Respiratory Institute
-
-
North Carolina
-
Greensboro, North Carolina, Forenede Stater, 27403
- Pulmonix LLC
-
Wilmington, North Carolina, Forenede Stater, 28401
- PMG Research of Wilmington
-
-
Washington
-
Everett, Washington, Forenede Stater, 98208
- Western Washington Medical Group
-
Seattle, Washington, Forenede Stater, 98122
- Swedish Medical Center
-
-
-
-
-
Hannover, Tyskland, 30625
- Fraunhofer-Institut für Toxikologie und Experimentelle Medizin ITEM
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Have a diagnosis of IPF 5 years from time of screening, confirmed at baseline
- Tolerated dose of pirfenidone 1602-2403 mg once daily (QD) for a minimum of 24 weeks required prior to and during screening
- Greater than or equal to (>=) 50 percent (%) and less than or equal to (<=) 100% of predicted forced vital capacity (FVC) at screening
- Stable baseline lung function as evidenced by a difference of less than (<) 10% in absolute FVC measurements (in liters) between screening and Day 1/Visit 2 prior to enrollment
- >=30% and <=90% of predicted diffusion capacity of the lung for carbon monoxide at screening
- Agree to use protocol defined methods of contraception
- Male participants must agree not to donate semen during the study and for at least 2 months (or as per local requirements) after the last dose of vismodegib
- Agree not to donate blood or blood products during the study and for at least 9 months (or as per local requirements) after the last dose of study treatment
Exclusion Criteria:
- Prior treatment with vismodegib or any Hh-pathway inhibitor
- Evidence of other known causes of interstitial lung disease
- Hospitalization due to an exacerbation of IPF within 4 weeks prior to or during screening
- Lung transplant expected within 6 months of screening
- Evidence of clinically significant lung disease other than IPF
- Post-bronchodilator forced expiratory volume in 1 second/FVC ratio <0.7 at screening
- Any clinically significant medical disease (other than IPF) that is associated with an expected survival of <6 months, likely to require a change in therapy during the study
- Class IV New York Heart Association chronic heart failure or historical evidence of left ventricular ejection fraction <35%
- Known current malignancy or current evaluation for a potential malignancy
- Known immunodeficiency, including, but not limited to, human immunodeficiency virus infection
- Evidence of acute or chronic hepatitis or known liver cirrhosis
- Creatinine clearance <=30 milliliter per minute, calculated using the Cockcroft-Gault formula
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Vismodegib and Pirfenidone
Participants being treated with pirfenidone, will receive vismodegib 150 milligrams (mg) once daily and pirfenidone up to 2403 mg daily orally for 24 weeks.
|
Pirfenidone will be administered as per the dosage schedule mentioned in arm description.
Andre navne:
Vismodegib will be administered as per the dosage schedule mentioned in arm description.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Participants with Serious and Non-Serious Adverse Events
Tidsramme: Baseline up to 28 weeks
|
An adverse event is any untoward medical occurrence in a participant who receive study drug without regard to possibility of causal relationship.
A serious adverse event is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
|
Baseline up to 28 weeks
|
|
Percentage of Participants with Discontinuation of Any Study Medication Due to a Drug-Related Adverse Event
Tidsramme: Baseline up to 28 weeks
|
An adverse event is any untoward medical occurrence in a participant who receive study drug without regard to possibility of causal relationship.
Relatedness to the study drug will be assessed by the investigator.
|
Baseline up to 28 weeks
|
|
Percentage of Participants with Dose Modifications Due to Laboratory Abnormalities and Adverse Events
Tidsramme: Baseline up to 28 weeks
|
An adverse event is any untoward medical occurrence in a participant who receive study drug without regard to possibility of causal relationship.
|
Baseline up to 28 weeks
|
|
Percentage of Participants with Clinically Meaningful Laboratory Abnormalities as Assessed by Investigator
Tidsramme: Baseline up to 28 weeks
|
Vital signs and laboratory parameters will be evaluated, and percentage of participants with any clinically meaningful abnormalities as assessed by Investigator will be reported.
Laboratory abnormalities of National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade greater than (>) 3 will be considered clinical meaningful.
|
Baseline up to 28 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Total and Free Trough Plasma Concentrations of Vismodegib at Week 4 (Cmin, Wk4)
Tidsramme: Predose (0 hour) at Week 4
|
Total plasma concentration of vismodegib = free (unbound) vismodegib plasma concentration + alpha-1-acid glycoprotein (AAG)-bound vismodegib plasma concentration.
|
Predose (0 hour) at Week 4
|
|
Total and Free Trough Plasma Concentrations of Vismodegib at Week 12 (Cmin, Wk12)
Tidsramme: Predose (0 hour) at Week 12
|
Total plasma concentration of vismodegib = free (unbound) vismodegib plasma concentration + AAG-bound vismodegib plasma concentration.
|
Predose (0 hour) at Week 12
|
|
Total and Free Trough Plasma Concentrations of Vismodegib at Week 24 (Cmin, Wk24)
Tidsramme: Predose (0 hour) at Week 24
|
Total plasma concentration of vismodegib = free (unbound) vismodegib plasma concentration + AAG-bound vismodegib plasma concentration.
|
Predose (0 hour) at Week 24
|
|
Total and Free Trough Plasma Concentrations of Vismodegib at Safety Follow-up Visit (Cmin, SFU)
Tidsramme: At Day 30 post last dose (last dose = 24 weeks) (up to 28 weeks)
|
Total plasma concentration of vismodegib = free (unbound) vismodegib plasma concentration + AAG-bound vismodegib plasma concentration.
|
At Day 30 post last dose (last dose = 24 weeks) (up to 28 weeks)
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Luftvejssygdomme
- Lungesygdomme
- Fibrose
- Lungefibrose
- Idiopatisk lungefibrose
- Lægemidlers fysiologiske virkninger
- Agenter fra det perifere nervesystem
- Analgetika
- Sensoriske systemagenter
- Anti-inflammatoriske midler, ikke-steroide
- Analgetika, ikke-narkotisk
- Anti-inflammatoriske midler
- Antirheumatiske midler
- Antineoplastiske midler
- Pirfenidon
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- GB29764
- 2015-003481-81 (EudraCT nummer)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .